(Washington, D.C.) —Pharmaceutical Care Management Association (PCMA) President and CEO JC Scott released the following statement on today’s action in the House Judiciary Committee on legislation aimed at increasing competition in the prescription drug marketplace.

“We applaud the House Judiciary Committee for addressing the need to increase competition in the prescription drug marketplace. H.R. 965, The Creating and Restoring Equal Access to Equivalent Samples “CREATES” Act, H.R. 2375, the Preserve Access to Affordable Generics and Biosimilars Act, and H.R. 2374, the Stop Significant and Time-wasting Abuse Limiting Legitimate Innovation of New Generics Act are each important steps toward thwarting brand drug manufacturer tactics to prevent generics and biosimilars from entering the market.

Pharmacy benefit managers (PBMs) serve as the only check in the prescription drug supply chain against drugmakers’ sole power to set and raise prices. Allowing more generic and biosimilar medications to market will allow PBMs to encourage even greater competition among drugmakers.

Regarding H.R. 2376, the Prescription Pricing for People Act of 2019, we welcome a thorough examination by the Federal Trade Commission into competition in the prescription drug supply chain that includes other entities, including prescription drug wholesalers and drug manufacturers.

We look forward to working with Congress and the Administration on these important issues.”